SG Americas Securities
NMRA icon

SG Americas Securities’s Neumora Therapeutics NMRA Stock Holding History

SG Americas Securities’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,178
Closed -$33K – 3581
2026
Q1 		$33K Sell
17,178
-48,898
-74% -$127K ﹤0.01% 3059
2025
Q4 		$118K Buy
66,076
+579
+0.9% +$1.27K ﹤0.01% 3158
2025
Q3 		$119K Sell
65,497
-23,572
-26% -$38.1K ﹤0.01% 3008
2025
Q2 		$65K Sell
89,069
-23,326
-21% -$17.7K ﹤0.01% 2726
2025
Q1 		$112K Buy
112,395
+98,276
+696% +$168K ﹤0.01% 2959
2024
Q4 		$150K Sell
14,119
-7,462
-35% -$89.4K ﹤0.01% 2404
2024
Q3 		$285K Sell
21,581
-36,026
-63% -$420K ﹤0.01% 2194
2024
Q2 		$566K Buy
+57,607
New +$596K ﹤0.01% 1614
2024
Q1 		– Sell
-6,308
Closed -$108K – 3276
2023
Q4 		$108K Buy
+6,308
New +$77.4K ﹤0.01% 2708

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's NMRA Position: Q2 2026 in Review

SG Americas Securities sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 17,178 shares — an estimated $33K sold.

SG Americas Securities first reported a position in NMRA in Q4 2023 and held it in 9 quarters. The position peaked at $566K in Q2 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • SG Americas Securities reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 17,178 Neumora Therapeutics shares in Q2 2026, an estimated $33K.
  • SG Americas Securities first reported a position in Neumora Therapeutics in Q4 2023 and held it in 9 quarters.
  • SG Americas Securities's Neumora Therapeutics position peaked at $566K in Q2 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.